Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does that mean that there will be plenty of shares available at a price around $1.50 in 2 days?
QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING
Download as PDFNOVEMBER 29, 2021 3:50PM EST
CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 5,880,000 shares of the Company’s common stock at a purchase price of $1.50 per share pursuant to a registered direct offering. The closing of the offering is expected to occur on or about December 1, 2021, subject to the satisfaction of customary closing conditions.
A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
The offering is conditioned upon the Company receiving a waiver from a prior investor of certain rights, inclusive of a 30-day lock-up of common stock by such investor at prices below $3.00 per share and an agreement with such investor to reprice previously issued warrants to purchase up to approximately 5.4 million shares of common stock at a revised exercise price of $2.00 per share and a six-month extension of the warrants’ respective termination dates.
This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-232798) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Qualigen Therapeutics, Inc.
Qualigen is a biotechnology company focused on developing novel therapeutic products for the treatment of cancer, as well as maintaining and expanding its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics for 20 years. Our therapeutics pipeline includes cancer drug compounds such as QN-247 and RAS-F. By combining our demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.
Qualigen Forward-Looking Statements
This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's prospects and strategy for the development of therapeutic drug candidates and the consummation of the offering. Actual events or results may differ from the Company's expectations. For example, there can be no assurance that the Company will successfully consummate the offering, develop any drugs (including QN-247 and RAS-F); that preclinical development of the Company's drugs (including QN-247 and RAS-F) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs will receive required regulatory approvals (including Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's currently owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products (including QN-247 and RAS-F); or that the Company will be able to maintain or expand market demand and/or market share for the Company's diagnostic products. The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business can be found in the Company's prior filings with the Securities and Exchange Commission, including its most recent Form 10-K, all of which available at www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Relations:
For further information: David Kugelman
Atlanta Capital Partners, LLC
(404) 856-9157 or (866) 692-6847 Toll Free - U.S. & Canada
dk@atlcp.com
Tony Schor
Investor Awareness, Inc.
(847) 971-0922
tony@investorawareness.com
What does that mean?
That company BST Partners Inc., was started in 2018...
What does that involve for the RGBP shareholders? Too many shady things....
But I am tired of all these traumatizing manipulations and uncertainties...
I am proud of her... I am Romanian, , too
Florida Therapeutics is named after the founder’s mother, Florica, of Romanian descent, who struggled with and passed due to leukemia...
Who is in charge of this new company?
Yes, quite mysterious... Will anything good for the investors come out of it?
On their website, CSC states:
WHO WE ARE
Keeping your business in compliance. Streamlining operations. Helping your business expand globally. Protecting your brand online. CSC does whatever it takes to make your business run smoother.
CSC – HEADQUARTERS
251 Little Falls Drive
Wilmington, DE USA 19808
Toll Free: +1 866 403 5272
Outside United States: +1 302 636 5400
Facsimile: +1 302 636 5454
I called the company that is located at the address provided by Canary Oncoceutics. I was told that they are a registered agent for other companies. So, they might do that for Canary, but they cannot disclose that information....
Canary Oncoceutics Partners, LLC is registered in Delaware.
ile Number: 6374625 Incorporation Date / Formation Date: 11/8/2021
(mm/dd/yyyy)
Entity Name: CANARY ONCOCEUTICS PARTNERS, LLC
Entity Kind: Limited Liability Company Entity Type: General
Residency: Domestic State: DELAWARE
REGISTERED AGENT INFORMATION
Name: CORPORATION SERVICE COMPANY
Address: 251 LITTLE FALLS DRIVE
City: WILMINGTON County: New Castle
State: DE Postal Code: 19808
Phone: 302-636-5401
Checking by the address provided, I found another company there- CSC Family of Businesses
CSC OFFICE LOCATIONS
Headquartered in Wilmington, Delaware, USA, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. Wherever your business operates around the world, CSC is there to help. We have a presence in all 50 U.S. states, as well as many jurisdictions on four different continents.
I could not find any information on Canary Oncoceutics Partners, LLC ...
Green!
When do you expect "the big run?"
What is going to become of all these patents?
It happens each time, not just on Fridays....
Why does it always go down on "good news?" Is it because there is too much shorting when it rises on expectations? And, then, it is pushed down by all these shorters that have to cover? Is anything going to change after September 28?
Is this going to move higher anytime soon?
Red close.... Horrible....
I just checked with TD Ameritrade. I was told that they do not trade this.....
If it is not current, some brokerages do not even allow buys of this anymore... IT IS NOT CURRENT... So, how do you buy it?
Is this current now?
RGBPP, not RGBP, went to 0.175.
Can you post the link?
Did you sell half on the run yesterday?
Will a lot of people sell tomorrow? Is the price likely to go down?
That is why the price went up yesterday... last day to become a shareholder of record for the dividend...
If I buy tomorrow, do I appear as a shareholder of record?
If I buy tomorrow, do I appear as a shareholder of record?
After the record date, June 24, 2021... Before the dividend is paid... Not tomorrow...
It is June 17 today and the closing price is 0.017...
They advised me to talk to the CEO of the company about it, because they cannot disclose too much... Has anyone talked to him recently?
I called them today. And they told me that Ben Borgers, the auditor for RGBP, is on a vacation until after the first week of July. So much for getting the audit done soon...
Soon? Someone from that CPA firm told me that an audit can take 6 months... A week ago, she confirmed that this audit, of RGBP, is “in process” but it can take 6 month... Have you gotten better informationa?
When and if....
Is this going further down? What made it really go up?
1 of these preferred shares can convert to how many common ones?
Which one of those might happen first?